In December, Novo Nordisk submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of substances that outsourcing facilities may use in ...
Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different ...
it forecasts its weight-loss offering to primarily be composed of "evolving" oral solutions as well as generic liraglutide, the chemical name of another Novo Nordisk product, Saxenda. Analysts at ...
Zacks Investment Research on MSN2d
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback